Gyre Therapeutics, Inc. Debt Securities, Available-for-sale
Gyre Therapeutics, Inc. (GYRE) had Debt Securities, Available-for-sale of $17.45 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Investments
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-07
- 2026-06-30: Debt Securities, Available-for-sale $17.45M.
- 2025-12-31: Debt Securities, Available-for-sale $28.09M.
- 2025-09-30: Debt Securities, Available-for-sale $67.18M.
- 2025-06-30: Debt Securities, Available-for-sale $68.05M.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2026-06-30 | $17.45M 10-Q · filed 2026-08-07 | |
| 2025-12-31 | $28.09M 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $67.18M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $68.05M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $39.90M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $42.73M 10-Q · filed 2025-11-07 | |
| 2024-09-30 | $3.18M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $2.88M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $3.90M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $29.29M 10-K · filed 2025-03-17 | $5.86M 10-K · filed 2024-03-27 |
| 2022-12-31 | $21.67M 10-K · filed 2023-03-30 | |
| 2022-09-30 | $23.09M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $75.39M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $34.82M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $46.85M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |